← SynDRA

VEMURAFENIB

SynDRA canonical compound SYN0024127 — structure-anchored drug synonym record

All known targets

• BRAF
• RAF1
• ARAF
• MAP4K5
• TGFBR2
• RIPK3
• RIPK2
• PTK6
• Map2k4
• MAP2K5
• ASPH
• KRAS

Mechanisms of action (all sources)

• RAF inhibitor
• BRAF INHIBITOR
• Serine/threonine-protein kinase B-raf inhibitor
• RAF1 INHIBITOR
• BRAF MODULATOR

Drug classes

• Protein Kinase Inhibitors
• Antineoplastic Agents
• Enzyme Inhibitors
• Kinase Inhibitor
• Cytochrome P450 1A2 Inhibitors
• P-Glycoprotein Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 42611257
• ChEMBL: CHEMBL1229517
• DrugBank: DB08881
• ChEBI: CHEBI:63637
• KEGG: D09996
• RxNorm: 1147220
• PDB: 032
• Wikipedia: Vemurafenib
• TTD: D0Y9EW
• LINCS BRD: BRD-K56343971

Synonyms

• PLX-4032
• RO 5185426
• RG 7204
• zelboraf
• Ro 51-85426
• PLX4032
• RG-7204
• RO-5185426
• RO-51-85426
• Zelboraf
• RG7204
• RO5185426
• Zelboraf (TN)
• Vemurafenib (BRAF inhibitor)
• PLX 4032
• N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide
• Vemurafenib (PLX4032, RG7204)
• N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
• Vemurafenib (PLX4032)
• 207SMY3FQT
• CHEBI:63637
• MFCD18074504
• NSC761431
• N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide
• N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide
• Vemurafenib;PLX-4032
• 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-
• 1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-
• N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide
• N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
• n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide
• Vemurafenib [USAN]
• Vemurafenib [USAN:INN]
• UNII-207SMY3FQT
• vemurafenibum
• HSDB 8143
• N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide
• 3og7

Reported adverse events

• Arthralgia
• Cough
• Fatigue
• Headache
• Hypersensitivity
• Neoplasm
• Neutropenia
• Pancreatitis
• Photosensitivity reaction
• Rash
• Rash papular
• Decreased appetite